1-8 of 8
Liat Bird
Close
Sort by
Journal Articles

HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma

Caron Jacobson, Nadja Kopp, Jacob V. Layer, Robert A. Redd, Sebastian Tschuri, Sarah Haebe, Diederik van Bodegom, Liat Bird, Amanda L. Christie, Alexandra Christodoulou, Amy Saur, Trevor Tivey, Stefanie Zapf, Deepak Bararia, Ursula Zimber-Strobl, Scott J. Rodig, Oliver Weigert, David M. Weinstock
Journal: Blood
Blood (2016) 128 (21): 2517–2526.
https://doi.org/10.1182/blood-2016-04-711176
Published: 2016
Includes: Supplemental data
Journal Articles

Newer-Generation HSP90 Inhibitors Can Overcome Ibrutinib Resistance and Suppress Proliferation in Human Mantle Cell Lymphoma in Vitro and in Vivo

Nadja Kopp, MA, Sebastian Tschuri, Sarah Haebe, Diederik van Bodegom, PhD, Liat Bird, Amanda L. Christie, Amy Saur, Alexandra N. Christodoulou, Trevor Tivey, Andrew L Kung, MD PhD, Oliver Weigert, MD, David Weinstock, MD
Journal: Blood
Blood (2014) 124 (21): 1686.
https://doi.org/10.1182/blood.V124.21.1686.1686
Published: 2014
Journal Articles

Newer-Generation HSP90 Inhibitors Have Potent Activity Against Human Mantle Cell Lymphoma in Vitro and in Vivo

Oliver Weigert, MD, Diederik van Bodegom, PhD, Liat Bird, Amy Saur, Trevor Tivey, Nadja Kopp, Andrew L. Kung, MD, PhD, David Weinstock, MD
Journal: Blood
Blood (2012) 120 (21): 1651.
https://doi.org/10.1182/blood.V120.21.1651.1651
Published: 2012
Journal Articles

BET Bromodomain Inhibition Targets Both c-Myc and IL7R in Acute Lymphoblastic Leukemia

Nadja Kopp, Christopher J. Ott, PhD, Liat Bird, Ronald Paranal, Jun Qi, PhD, Teresa Bowman, Scott J. Rodig, MD, PhD, Andrew L. Kung, MD, PhD, James E. Bradner, MD, David Weinstock, MD
Journal: Blood
Blood (2012) 120 (21): 672.
https://doi.org/10.1182/blood.V120.21.672.672
Published: 2012
Journal Articles

BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia

Christopher J. Ott, Nadja Kopp, Liat Bird, Ronald M. Paranal, Jun Qi, Teresa Bowman, Scott J. Rodig, Andrew L. Kung, James E. Bradner, David M. Weinstock
Journal: Blood
Blood (2012) 120 (14): 2843–2852.
https://doi.org/10.1182/blood-2012-02-413021
Published: 2012
Includes: Supplemental data
Journal Articles

Differences in signaling through the B-cell leukemia oncoprotein CRLF2 in response to TSLP and through mutant JAK2

Diederik van Bodegom, Jun Zhong, Nadja Kopp, Chaitali Dutta, Min-Sik Kim, Liat Bird, Oliver Weigert, Jeffrey Tyner, Akhilesh Pandey, Akinori Yoda, David M. Weinstock
Journal: Blood
Blood (2012) 120 (14): 2853–2863.
https://doi.org/10.1182/blood-2012-02-413252
Published: 2012
Includes: Supplemental data
Journal Articles

HSP90 Inhibition Targets JAK2 and Is Highly Effective in CRLF2-Rearranged Acute Lymphoblastic Leukemia

Oliver Weigert, MD, Liat Bird, Nadja Kopp, Andrew A. Lane, MD, PhD, Bjoern Chapuy, MD, PhD, Diederik van Bodegom, Sachie Marubayashi, Akinori Yoda, PhD, Vincent Romanet, MSc, Masato Murakami, MD, PhD, Stephen E. Sallan, MD, Ross L Levine, MD, Andrew L. Kung, MD, PhD, Thomas Radimerski, PhD, David M Weinstock, MD
Journal: Blood
Blood (2011) 118 (21): 576.
https://doi.org/10.1182/blood.V118.21.576.576
Published: 2011
Journal Articles

Genetic Resistance to JAK2 Enzymatic Inhibitors Is Overcome by HSP90 Inhibition

Oliver Weigert, MD, Andrew A. Lane, MD, PhD, Liat Bird, Nadja Kopp, Angela V Toms, Ph.D., Christoph Gaul, Eric Vangrevelinghe, Alain De Pover, Catherine H. Regnier, PhD, Dirk Erdmann, Francesco Hofmann, PhD, Michael Eck, Andrew L. Kung, MD, PhD, Thomas Radimerski, PhD, David M Weinstock, MD
Journal: Blood
Blood (2011) 118 (21): 62.
https://doi.org/10.1182/blood.V118.21.62.62
Published: 2011